HeartFlow
HeartFlow (HTFL) is a publicly traded Imaging & Diagnostics AI company founded in 2007 and based in San Francisco, United States.
HeartFlow was incorporated in 2007 by Charles Taylor and Christopher Zarins and is headquartered in San Francisco. Its software analyzes coronary CT angiography scans to build patient-specific models of the coronary arteries: FFRct Analysis calculates blood flow to find narrowings that limit it, and Plaque Analysis measures and characterizes plaque. HeartFlow bills its customer accounts each time a physician chooses to review an analysis, and FFRct Analysis produced 98% of its 2025 revenue. It listed on Nasdaq in August 2025 under the ticker HTFL. For the second quarter of 2026 it reported revenue of $64.1M, up 48% from a year earlier, with an 83% gross margin, and it raised its 2026 revenue guidance to $246M-$250M from $228M-$232M. It held $246.8M of cash, cash equivalents and investments on June 30, 2026.
HeartFlow's analyses have been used for more than 750,000 patients at more than 1,800 institutions worldwide. A Category I CPT code for Plaque Analysis took effect on Jan. 1, 2026, and five of the seven Medicare Administrative Contractors had issued coverage policies for it by March 2026. That gives AI plaque quantification a standard billing path, and HeartFlow's CEO called Plaque a second growth engine in August 2026. It competes with Cleerly in coronary imaging AI.
At a glance
Total raised
Undisclosed
Headcount
501-1k
Headquarters
San Francisco
United StatesFounded
2007
Status
Public
Subsector
Health Tech, ranked
Top 25 Health Tech companies →Funding history
Total raised
—
Rounds tracked
0
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
